Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Patients diagnosed with Neuroendocrine Tumors (NET) often are also diagnosed with Neuroendocrine Liver Metastases (NLM) during the course of their disease. NLM can cause significant morbidity and mortality, oftentimes much more than compared to patients with NET. Treatment options have been limited in the past, focusing on surgical resections, for which only a minority of patients are candidates. However, developments of new treatment modalities have progressed rapidly and patients with NLM now have significantly more options, including surgical-directed therapies; liver-directed therapies; and nonsurgical, non-liver-directed therapies. This review provides information about the roles of hepatic resection, orthotopic liver resection, radiofrequency ablation, hepatic artery embolization and hepatic artery chemoembolization, hepatic artery radioembolization and selective internal radiation therapy, peptide receptor radionuclide therapy, systemic chemotherapy, biotherapies including somatostatin analogs and interferon-α, vascular endothelial growth factor and mTOR targets, and microRNA-regulated pathways. Given these new options, the clinician can tailor therapy specific to the patient diagnosed with NLM, thereby giving the patient the best possible chance of prolonged survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These cases highlight instances where PRRT achieved remarkable therapeutic responses, demonstrating its efficacy by delivering targeted radiation to NET cells while sparing healthy tissues [102].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590 · cited 1×
“Newer positron emission tomography (PET) imaging platforms such as 68Gallium-DOTA0Tyr3octreotide-PET and 68Gallium-DOTA0Tyr3octreotate-PET are increasingly used to evaluate tumors as they are even more sensitive to radiotracer uptake [40] and may be able to better predict responsiveness to PRRT…”
BackgroundEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · cited 1×
“The more the tumor expresses somatostatin receptors as compared to the surrounding tissue, the more effective the PRRT will be.”
BackgroundRinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456 · cited 1×
“In one study with 310 patients, median overall survival rate from initiation of PRRT was 46 months [47].”
BackgroundDisrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation
Mayr, C., Hemann, M. T., & Bartel, D. P. (2007) · Science · doi:10.1126/science.1137999 · Cited by 1,100
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849 · cited 2×
“to a longer half-life of approximately two hours [61].”
BackgroundMoertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840 · cited 1×
“…fewer nodular liver metastatic lesions, local resection or thermal ablation is recommended; for a higher-tumor load due to unresectable multinodular disease or recurrent disease after resection, hepatic artery embolization, hepatic artery chemoembolization, or radioembolization is warranted [19].”
BackgroundMicroRNA expression and function in cancer
Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A., & Croce, C. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.006 · Cited by 780 · cited 1×
“Newer positron emission tomography (PET) imaging platforms such as 68Gallium-DOTA0Tyr3octreotide-PET and 68Gallium-DOTA0Tyr3octreotate-PET are increasingly used to evaluate tumors as they are even more sensitive to radiotracer uptake [40] and may be able to better predict responsiveness to PRRT…”
BackgroundStrosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J., & Kvols, L. (2011) · Cancer · doi:10.1002/cncr.25425 · Cited by 766 · cited 1×
“temozolomide and thalidomide showed a response rate of 45% [52], and a retrospective study of temozolomide and capecitabine showed a response rate of 70%, a median PFS of 18 months, and an overall 2-year survival of 92% [53].”
BackgroundYao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649 · cited 3×
“One review article found symptomatic and tumor response to octreotide, octreotide long-acting repeatable (LAR), lanreotide, and lanreotide slow-release depot (autogel) in 74.2%, 77.3%, 63.0%, and 67.5%, and in 57.4%, 69.8%, 46.6%, and 64.4%, respectively [72].”
BackgroundInfluentialYao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 647
Hepatic neuroendocrine metastases: does intervention alter outcomes?1
Chamberlain, R. S., Canes, D., Brown, K. T., Saltz, L., Jarnagin, W., Fong, Y., & Blumgart, L. H. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00222-2 · Cited by 622 · cited 2×
“It has been estimated that less than 20% of patients with metastatic neuroendocrine tumors are candidates for hepatic resection [14].”
BackgroundKouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607 · cited 1×
“Defining the treatment best suited for the tumor load is dependent on number and location of the lesions, invasiveness and size of the tumor, physiology and effects of hormone secretion, and extent of metastatic disease within the patient.”
BackgroundBoudreaux, J. P., Klimstra, D. S., Hassan, M. M., Woltering, E. A., Jensen, R. T., Goldsmith, S. J., Nutting, C., Bushnell, D. L., Caplin, M. E., & Yao, J. C. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb2a5 · Cited by 539 · cited 1×
“Interferon-α can ameliorate symptoms in 30% to 70% of patients [81, 82], and in some studies has shown promising results with tumor response rate or stabilization in up to 70% of patients [82].”
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Kulke, M. H., Stuart, K., Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Vincitore, M., Michelini, A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6046 · Cited by 513 · cited 1×
“temozolomide and thalidomide showed a response rate of 45% [52], and a retrospective study of temozolomide and capecitabine showed a response rate of 70%, a median PFS of 18 months, and an overall 2-year survival of 92% [53].”
BackgroundTreatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Mitry, E., Baudin, E., Ducreux, M., Sabourin, J.-C., Rufié, P., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690325 · Cited by 496 · cited 1×
“…fewer nodular liver metastatic lesions, local resection or thermal ablation is recommended; for a higher-tumor load due to unresectable multinodular disease or recurrent disease after resection, hepatic artery embolization, hepatic artery chemoembolization, or radioembolization is warranted [19].”
BackgroundGupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 433 · cited 1×
“Having said this, a number of reports reveal worse outcomes for patients with greater than 50% liver involvement [28, 29].”
BackgroundKennedy, A. S., Dezarn, W. A., McNeillie, P., Coldwell, D., Nutting, C., Carter, D., Murthy, R., Rose, S., Warner, R. R. P., Liu, D., et al. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31815e4557 · Cited by 424 · cited 2×
“is the stabilization of extensive disease allowing for longer survival periods [38].”
BackgroundMODLIN, I. M., PAVEL, M., KIDD, M., & GUSTAFSSON, B. I. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 410
Cytoreductive hepatic surgery for neuroendocrine tumors.
Gp, M., Nagorney, D. M., Lk, K., Cg, M., & Cs, G. (1990) · PubMed · Cited by 381
Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?
Touzios, J. G., Kiely, J. M., Pitt, S. C., Rilling, W. S., Quebbeman, E. J., Wilson, S. D., & Pitt, H. A. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000161981.58631.ab · Cited by 362
Kwekkeboom, D. J., Krenning, E. P., Lebtahi, R., Komminoth, P., Kos-Kudła, B., de Herder, W. W., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225951 · Cited by 349 · cited 1×
“This technique allows precise destruction of tumor cells [42, 43], with little interference of nontumor tissue, except for some exposure of renal, bladder, and bone marrow tissues [44].”
BackgroundYang, Z., Tang, L. H., & Klimstra, D. S. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31821a0696 · Cited by 332 · cited 1×
“The importance of tumor grade to patient’s outcomes after resection has been confirmed by several investigations [10, 11].”
BackgroundA phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603419 · Cited by 317 · cited 1×
“Two mTOR inhibitors have been developed and approved for use in renal cell carcinomas [92], everolimus, and temsirolimus, and have been studied in NETs [41, 93–95].”
Srirajaskanthan, R., Kayani, I., Quigley, A. M., Soh, J., Caplin, M. E., & Bomanji, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066134 · Cited by 310 · cited 13×
“Peptide receptor radionuclide therapy (PRRT) is an upcoming option with enticing advantages, most useful in symptomatic patients with somatostatin receptor-positive tumors, who are not surgical candidates.”
BackgroundInfluential90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
Bushnell, D. L., O'Dorisio, T. M., O'Dorisio, M. S., Menda, Y., Hicks, R. J., Van Cutsem, E., Baulieu, J.-L., Borson-Chazot, F., Anthony, L., Benson, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8585 · Cited by 306 · cited 1×
“177Lu-DOTA0Tyr3octreotate seems to be the most effective PRRT, with a tumor response rate of 35% and tumor stabilization of 80% to 90% of NETs [44], versus 90Y-DOTA0Tyr3octreotide with a tumor response of 4% and tumor stabilization of 70% [46].”
BackgroundSteinmüller, T., Kianmanesh, R., Falconi, M., Scarpa, A., Taal, B., Kwekkeboom, D. J., Lopes, J. M., Perren, A., Nikou, G., Yao, J., et al. (2008) · Neuroendocrinology · doi:10.1159/000111037 · Cited by 296 · cited 2×
“In 2008, the ENETS proposed guideline for surgical resection based on the 3 distinct patterns of liver involvement: (1) “simple” pattern of metastasis located in one or two contiguous lobes (20–25%), (2) “complex” pattern where there is one major focus and other lesions are contained in the contralateral lobe (10–15%)…”
BackgroundMethodRadioembolization with selective internal radiation microspheres for neuroendocrine liver metastases
King, J., Quinn, R., Glenn, D. M., Janssen, J., Tong, D., Liaw, W., & Morris, D. L. (2008) · Cancer · doi:10.1002/cncr.23685 · Cited by 284 · cited 4×
“Radiographic and serology studies revealed median survival of 35 months with a followup of 41 months, and 55% of patients had complete or partial responses [37].”
BackgroundInfluentialExpression of vascular endothelial growth factor in digestive neuroendocrine tumours
Terris, Scoazec, Rubbia, Bregeaud, Pepper, Ruszniewski, Belghiti, FLÉjou, & Degott (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00321.x · Cited by 279 · cited 3×
“NETs and NLMs frequently overexpress the vascular endothelial growth factor (VEGF) ligand and receptor (VEGFR) [89].”
BackgroundLIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE CARCINOMA: An Analysis of 103 Patients
Lehnert, T. (1998) · Transplantation · doi:10.1097/00007890-199811270-00007 · Cited by 268 · cited 1×
“However, extent of surgery at the time of transplantation and age of recipient were significant prognostic factors for survival [15].”
BackgroundTreatment with cisplatin and etoposide in patients with neuroendocrine tumors
Fj�llskog, M.-L. H., Granberg, D. P. K., Welin, S. L. V., Eriksson, C., �berg, K. E., Janson, E. T., & Eriksson, B. K. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1101::aid-cncr1426>3.0.co;2-v · Cited by 262 · cited 1×
“Even with increased response rates, median survival times are of short duration of 8 to 11 months [56].”
BackgroundMicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M. G., Wang, Y., Libutti, S. K., Nakakura, E. K., Golub, T. R., & Hanahan, D. (2009) · Genes & Development · doi:10.1101/gad.1820109 · Cited by 260 · cited 2×
“This study also found that microRNA-210, -431, and -424 were up-regulated in metastases as compared with tumors, suggesting that certain microRNAs could be used to predict the probability of metastasis [101].”
BackgroundSaltz, L., Trochanowski, B., Buckley, M., Heffernan, B., Niedzwiecki, D., Tao, Y., & Kelsen, D. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1<244::aid-cncr2820720143>3.0.co;2-q · Cited by 260 · cited 1×
“Ninety-seven percent of the sample immediately felt improvement of symptoms after the procedure, where median disease-free survival was 1.3 years and overall survival at 6 years after RFA [21].”
BackgroundInfluentialFrilling, A., Li, J., Malamutmann, E., Schmid, K.-W., Bockisch, A., & Broelsch, C. E. (2009) · British Journal of Surgery · doi:10.1002/bjs.6468 · Cited by 257 · cited 5×
“Between 80% to 95% of gastroenteropancreatic, NETs express somatostatin receptors [40] as demonstrated by 111In-pentetreotide scans (OctreoScan, Covidien-Mallinckrodt Imaging, Hazelwood, MO 63042) [41], so PRRT may be useful for a large percentage of NLMs, perhaps in up to 25% of patients [12].”
BackgroundInfluentialMazzaglia, P. J., Berber, E., Milas, M., & Siperstein, A. E. (2007) · Surgery · doi:10.1016/j.surg.2007.01.036 · Cited by 256 · cited 3×
“[21, 22] The complications can include carcinoid crisis, liver abscesses, biliopleural fistulas, bile leakage, and pleural effusion, as well as postablation syndrome, and liver failure.”
BackgroundEriksson, B., Klöppel, G., Krenning, E., Ahlman, H., Plöckinger, U., Wiedenmann, B., Arnold, R., Auernhammer, C., Körner, M., Rindi, G., et al. (2008) · Neuroendocrinology · doi:10.1159/000111034 · Cited by 254 · cited 1×
“However, in patients with progressive disease, combination therapy may be a viable option [85].”
BackgroundArnold, R., Rinke, A., Klose, K.-J., Müller, H.-H., Wied, M., Zamzow, K., Schmidt, C., Schade-Brittinger, C., Barth, P., Moll, R., et al. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00481-7 · Cited by 254 · cited 1×
“Two demonstrated increased 5-year survival rate [70] and median survival time [83] in the combination group versus the octreotide-only group, 57% versus 37% and 51 months versus 35 months, respectively; but another trial showed minimal response rates [84].”
ResultBajetta, E., Catena, L., Procopio, G., De Dosso, S., Bichisao, E., Ferrari, L., Martinetti, A., Platania, M., Verzoni, E., Formisano, B., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0306-6 · Cited by 240 · cited 1×
“Platinum-based chemotherapy regimens may be useful in patients with high-grade, poorly differentiated NETs, with response rates of 42% to 80% with the use of cisplatin and etoposide [54–56], and 78% with use of oxaliplatin-based regimens [57].”
BackgroundElias, D., Lasser, P., Ducreux, M., Duvillard, P., Ouellet, J.-F., Dromain, C., Schlumberger, M., Pocard, M., Boige, V., Miquel, C., et al. (2003) · Surgery · doi:10.1067/msy.2003.114 · Cited by 237 · cited 1×
“that had incomplete resection still did well [9].”
Long-term survival after surgical management of neuroendocrine hepatic metastases
Glazer, E. S., Tseng, J. F., Al-Refaie, W., Solorzano, C. C., Liu, P., Willborn, K. A., Abdalla, E. K., Vauthey, J.-N., & Curley, S. A. (2010) · HPB · doi:10.1111/j.1477-2574.2010.00198.x · Cited by 230 · cited 2×
“series have reported similar results [4, 6].”
BackgroundKölby, L., Persson, G., Franzén, S., & Ahrén, B. (2003) · British Journal of Surgery · doi:10.1002/bjs.4149 · Cited by 222 · cited 1×
“Two demonstrated increased 5-year survival rate [70] and median survival time [83] in the combination group versus the octreotide-only group, 57% versus 37% and 51 months versus 35 months, respectively; but another trial showed minimal response rates [84].”
ResultZhang, W., Dahlberg, J. E., & Tam, W. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070070 · Cited by 221
Van Essen, M., Krenning, E. P., De Jong, M., Valkema, R., & Kwekkeboom, D. J. (2007) · Acta Oncologica · doi:10.1080/02841860701441848 · Cited by 221 · cited 1×
“Although patients in this study were included only if it appeared that they could be completely resected, patients that had incomplete resection still did well [9].”
BackgroundJanson, E. T., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083916 · Cited by 204
Frank, M. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00146-x · Cited by 191 · cited 1×
“The greatest response rates have been witnessed with octreotide doses of 30 mg/day or greater or with lanreotide doses of 5 mg/day or greater [74]; octreotide doses greater than 60 mg/day likely do not have additive effect due to oversaturation of receptor sites [75].”
BackgroundLe Treut, Y. P., Grégoire, E., Belghiti, J., Boillot, O., Soubrane, O., Mantion, G., Cherqui, D., Castaing, D., Ruszniewski, P., Wolf, P., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02233.x · Cited by 189 · cited 1×
“In this study, primary tumor location in the duodenum or pancreas was noted to be an indicator of poor prognosis [16].”
BackgroundRosenau, J., Bahr, M. J., von Wasielewski, R., Mengel, M., Schmidt, H. H. J., Nashan, B., Lang, H., Klempnauer, J., Manns, M. P., & Boeker, K. H. W. (2002) · Transplantation · doi:10.1097/00007890-200202150-00012 · Cited by 188 · cited 1×
“Expression of p53 did not appear to influence survival [18].”
BackgroundRamanathan, R. K., Cnaan, A., Hahn, R. G., Carbone, P. P., & Haller, D. G. (2001) · Annals of Oncology · doi:10.1023/a:1011632713360 · Cited by 181 · cited 1×
“Dacarbazine (DTIC) is another chemotherapy agent with proven effectiveness in pancreatic NETs, and in one phase II trial demonstrated a response rate of 34% [51].”
BackgroundVogl, T. J., Naguib, N. N. N., Zangos, S., Eichler, K., Hedayati, A., & Nour-Eldin, N.-E. A. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.08.008 · Cited by 180 · cited 3×
“Because of the observation that higher disease regression rate and longer length of regression with systemic chemotherapy after HAE was published [24], chemotherapy has been added to the embolic agents, and HACE is now generally favored over HAE.”
BackgroundInfluentialSchurr, P. G., Strate, T., Rese, K., Kaifi, J. T., Reichelt, U., Petri, S., Kleinhans, H., Yekebas, E. F., & Izbicki, J. R. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000232556.24258.68 · Cited by 178 · cited 3×
“Tumor size, number, and location have also been shown to influence postresection survival [4, 12].”
BackgroundMayo, S. C., de Jong, M. C., Bloomston, M., Pulitano, C., Clary, B. M., Reddy, S. K., Clark Gamblin, T., Celinski, S. A., Kooby, D. A., Staley, C. A., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1832-y · Cited by 178 · cited 4×
“This finding was not supported in several other investigations [2, 17].”
BackgroundResultInfluentialGLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy
Cantuaria, G., Fagotti, A., Ferrandina, G., Magalhaes, A., Nadji, M., Angioli, R., Penalver, M., Mancuso, S., & Scambia, G. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1144::aid-cncr1432>3.0.co;2-t · Cited by 166
The role of mTOR in the management of solid tumors: An overview
Strimpakos, A. S., Karapanagiotou, E. M., Saif, M. W., & Syrigos, K. N. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.09.006 · Cited by 160 · cited 1×
“Two mTOR inhibitors have been developed and approved for use in renal cell carcinomas [92], everolimus, and temsirolimus, and have been studied in NETs [41, 93–95].”
BackgroundMultimodal management of neuroendocrine liver metastases
Frilling, A., Sotiropoulos, G. C., Li, J., Kornasiewicz, O., & Plöckinger, U. (2010) · HPB · doi:10.1111/j.1477-2574.2010.00175.x · Cited by 159 · cited 2×
“complete surgical extirpation is an option for a very small percentage of the neuroendocrine cancer patient population [1].”
BackgroundHo, A. S., Picus, J., Darcy, M. D., Tan, B., Gould, J. E., Pilgram, T. K., & Brown, D. B. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.0933 · Cited by 158 · cited 1×
“reported results on 46 patients with NLMs who received HACE or HAE, and showed that there was no statistically significant survival benefit in a small subset of population that also had resection of the primary tumor, although mean survival after resection increased by a mean of 558 days [26].”
ResultKress, O., Wagner, H., Wied, M., Klose, K.-J., Arnold, R., & Alfke, H. (2003) · Digestion · doi:10.1159/000074522 · Cited by 150 · cited 1×
“Having said this, a number of reports reveal worse outcomes for patients with greater than 50% liver involvement [28, 29].”
BackgroundSaxena, A., Chua, T. C., Bester, L., Kokandi, A., & Morris, D. L. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181d3d24a · Cited by 148 · cited 2×
“Biochemical marker levels of chromogranin A fell in nearly 50% of survivors by 30 months [31].”
BackgroundAkyildiz, H. Y., Mitchell, J. C., Milas, M., SIPERSTEIN, A. E., & Berber, E. (2010) · Surgery · doi:10.1016/j.surg.2010.09.014 · Cited by 145 · cited 11×
“Mean survival extended 3.9 years after the first RFA treatment.”
BackgroundInfluentialTreatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Kaltsas, G. A., Papadogias, D., Makras, P., & Grossman, A. B. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01116 · Cited by 143 · cited 1×
“This technique allows precise destruction of tumor cells [42, 43], with little interference of nontumor tissue, except for some exposure of renal, bladder, and bone marrow tissues [44].”
BackgroundWelin, S., Janson, E., Sundin, A., Stridsberg, M., Lavenius, E., Granberg, D. O., Skogseid, B. M., Öberg, K., & Eriksson, B. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510107 · Cited by 133 · cited 1×
“Ninety-seven percent of the sample immediately felt improvement of symptoms after the procedure, where median disease-free survival was 1.3 years and overall survival at 6 years after RFA [21].”
BackgroundInfluentialVoortman, J., Lee, J., Killian, J. K., Suuriniemi, M., Wang, Y., Lucchi, M., Smith, W. I., Meltzer, P. S., Wang, Y., & Giaccone, G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008132107 · Cited by 132 · cited 1×
“Others are looking at genetic copy number alterations of tumor suppressor genes [87] and the detection and characterization of circulating tumor cells to reduce metastatic burden [88] as other possible avenues to treat NETs and NLMs.”
BackgroundUpdate on the Management of Neuroendocrine Hepatic Metastases
Madoff, D. C., Gupta, S. K., Ahrar, K., Murthy, R., & Yao, J. C. (2006) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000232177.57950.71 · Cited by 129 · cited 2×
“This is tempered by the fact that extent of liver involvement did not serve as an independent prognostic indicator [3].”
Backgroundvan Essen, M., Krenning, E. P., Kam, B. L. R., de Herder, W. W., Feelders, R. A., & Kwekkeboom, D. J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.068957 · Cited by 124 · cited 1×
“The tumors were categorized as low grade ( 2 mitotic figures/50 hpf and no necrosis), intermediate grade (2–50 mitotic figures/50 hpf and/or focal necrosis), and high grade (>50 mitotic figures/50 hpf and/or extensive necrosis).”
BackgroundAntiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors
Strosberg, J., & Kvols, L. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.2963 · Cited by 121 · cited 1×
“Preliminary data indicate that pasireotide may be useful in patients with symptoms refractory to octreotide, possibly controlling symptoms in up to 27% of these patients [76].”
BackgroundHepatic Neuroendocrine Metastases: Chemo- or Bland Embolization?
Pitt, S. C., Knuth, J., Keily, J. M., McDermott, J. C., Weber, S. M., Chen, H., Rilling, W. S., Quebbeman, E. J., Agarwal, D. M., & Pitt, H. A. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0640-6 · Cited by 117
Antiproliferative Effect of Somatostatin and Analogs
Bousquet, C., Puente, E., Buscail, L., Vaysse, N., & Susini, C. (2001) · Chemotherapy · doi:10.1159/000049159 · Cited by 116 · cited 1×
“Somatostatin exerts its affect by integration with one of five somatostatin receptors, ssts1−5 [59], but due to a half-life of only two minutes [60],”
BackgroundEfficient in vivo microRNA targeting of liver metastasis
Huynh, C., Segura, M., Gaziel-Sovran, A., Menéndez, S., Darvishian, F., Chiriboga, L., Levin, B., Meruelo, D., Osman, I., Zavadil, J., et al. (2011) · Oncogene · doi:10.1038/onc.2010.523 · Cited by 114 · cited 1×
“showed that anti-microRNA-182 targeting had a therapeutic effect against melanoma liver metastasis, which may be extended to other tumors [102].”
BackgroundNilsson, O., Kölby, L., Wängberg, B., Wigander, A., Billig, H., William‐Olsson, L., Fjälling, M., Forssell-Aronsson, E. B., & Ahlman, H. K. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.101 · Cited by 111 · cited 1×
“The largest study to date, with the longest followup, was done at the Cleveland Clinic [21], a prospective trial of 89 patients with NLMs who underwent 119 laparoscopic RFA sessions in total.”
BackgroundSaxena, A., Chua, T. C., Sarkar, A., Chu, F., Liauw, W., Zhao, J., & Morris, D. L. (2010) · Surgery · doi:10.1016/j.surg.2010.06.008 · Cited by 110 · cited 1×
“The importance of tumor grade to patient’s outcomes after resection has been confirmed by several investigations [10, 11].”
BackgroundUse of somatostatin analog in management of carcinoid syndrome
Vinik, A. I., & Moattari, A. R. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536042 · Cited by 104 · cited 1×
“The largest study to date, with the longest followup, was done at the Cleveland Clinic [21], a prospective trial of 89 patients with NLMs who underwent 119 laparoscopic RFA sessions in total.”
BackgroundRuebel, K. H., Leontovich, A. A., Stilling, G. A., Zhang, S., Righi, A., Jin, L. G., & Lloyd, R. V. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.161 · Cited by 102 · cited 2×
“Further, the same group determined that decreasing levels of microRNA-133a has an important role in the development, progression, and possible metastasis of midgut carcinoid tumors [97].”
BackgroundPlöckinger, U., & Wiedenmann, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.01.002 · Cited by 85
Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms
Cho, C. S., Labow, D. M., Tang, L. H., Klimstra, D. S., Loeffler, A. G., LEVERSON, G. E., Fong, Y., Jarnagin, W. R., D'Angelica, M. I., Weber, S. M., et al. (2008) · Cancer · doi:10.1002/cncr.23523 · Cited by 81 · cited 2×
“None of the patients with high-grade malignancy survived 5 years with a median survival of only 6 months [7].”
BackgroundTreatment of Malignant Midgut Carcinoid Tumours with A Long-Acting Somatostatin Analogue Octreotide
Öberg, K., Norheim, I., & Theodorsson, E. (1991) · Acta Oncologica · doi:10.3109/02841869109092409 · Cited by 80 · cited 1×
“The largest study to date, with the longest followup, was done at the Cleveland Clinic [21], a prospective trial of 89 patients with NLMs who underwent 119 laparoscopic RFA sessions in total.”
BackgroundTherapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
Auernhammer, C. J., & Göke, B. (2011) · Gut · doi:10.1136/gut.2009.204453 · Cited by 80 · cited 7×
“Between 80% to 95% of gastroenteropancreatic, NETs express somatostatin receptors [40] as demonstrated by 111In-pentetreotide scans (OctreoScan, Covidien-Mallinckrodt Imaging, Hazelwood, MO 63042) [41], so PRRT may be useful for a large percentage of NLMs, perhaps in up to 25% of patients [12].”
BackgroundInfluentialVitale, G., de Herder, W. W., van Koetsveld, P. M., Waaijers, M., Schoordijk, W., Croze, E., Colao, A., Lamberts, S. W. J., & Hofland, L. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3043 · Cited by 80 · cited 1×
“Others have examined the role of dopamine receptors and interferon-β [86] as other possible targets, but currently, neither of these targets seems promising at this time due to ineffectiveness and short half-life.”
BackgroundStrosberg, J., Cheema, A., & Kvols, L. K. (2011) · Cancer Control · doi:10.1177/107327481101800207 · Cited by 77 · cited 15×
“Patients that seem to benefit the most from PRRT have strong radiotracer uptake on OctreoScan, at least as much as the liver [41].”
BackgroundMethodInfluentialDetjen, K. M., Welzel, M., Farwig, K., Brembeck, F. H., Kaiser, A., Riecken, E.-O., Wiedenmann, B., & Rosewicz, S. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70143-0 · Cited by 71 · cited 1×
“Interferons have multiple antitumor effects [79], and they may upregulate somatostatin receptors in NETs [80], thereby providing a useful combination therapeutic option.”
BackgroundMáthé, Z., Tagkalos, E., Paul, A., Molmenti, E. P., Kob́ori, L., Fouzas, I., Beckebaum, S., & Sotiropoulos, G. C. (2010) · Transplantation · doi:10.1097/tp.0b013e3182081312 · Cited by 71 · cited 1×
“This finding was not supported in several other investigations [2, 17].”
ResultMurthy, R., Kamat, P. P., NUÑEZ, R. F., Madoff, D. C., Gupta, S. K., Salem, R., & Yao, J. C. (2008) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2007.09.006 · Cited by 69 · cited 2×
“progression-free survival (PFS) when compared to alternative treatments [36].”
BackgroundResultLiver Transplantation for Treatment of Metastatic Neuroendocrine Tumors
Ahlman, H., Friman, S., Cahlin, C., Nilsson, O., Jansson, S. K. G., Wängberg, B., & Olausson, M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.029 · Cited by 65 · cited 1×
“Unless 80%– 90% of the tumor load is debulked, treatment does not serve useful as palliation therapy to prolong survival and improve symptom control [20].”
BackgroundClinical Presentation and Management of Carcinoid Tumors
Kulke, M. H. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.04.004 · Cited by 64 · cited 7×
“Mean survival extended 3.9 years after the first RFA treatment.”
BackgroundInfluentialChristante, D., Pommier, S. J., Givi, B., & Pommier, R. F. (2008) · Surgery · doi:10.1016/j.surg.2008.08.037 · Cited by 57 · cited 2×
“Of the different types of neuroendocrine tumors, carcinoid tumors seem to consistently have better outcomes to the combination of HACE and HAI [21, 23, 30].”
BackgroundKamat, P. P., Gupta, S. K., Ensor, J., Murthy, R., Ahrar, K., Madoff, D. C., Wallace, M. J., & Hicks, M. E. (2007) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-007-9186-3 · Cited by 57 · cited 1×
“Regardless, these therapies have increased versatility as reflected in a study of 48 patients and 123 treatment sessions which revealed HACE or HAE could even benefit carefully selected patients with a tumor load of greater than 75% liver involvement, so long as the patients did not have additional risk factors [27].”
BackgroundFuture Aspects of Somatostatin- Receptor-Mediated Therapy
Öberg, K. (2004) · Neuroendocrinology · doi:10.1159/000080743 · Cited by 55 · cited 1×
“Side effects are infrequent, but nausea, stomach cramping or discomfort, diarrhea, steatorrhea, cardiac abnormalities and arrhythmias, hypothyroidism, and hypoglycemia may occur [40, 41, 77].”
BackgroundRahman, M. M., Qian, Z. R., Wang, E. L., Sultana, R., Kudo, E., Nakasono, M., Hayashi, T., Kakiuchi, S., & Sano, T. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604883 · Cited by 51 · cited 1×
“Additional studies are warranted in this area pertaining to microRNA-regulated pathways, but already possible therapeutic targets have been identified by researchers including the high-mobility group A proteins, HMGA1, HMGA2, and the microRNA family let-7 [103, 104].”
BackgroundWoltering, E. A., Mamikunian, P., Zietz, S., Krutzik, S. R., Go, V. L. W., Vinik, A. I., Vinik, E. J., O’Dorisio, T. M., & Mamikunian, G. (2005) · Pancreas · doi:10.1097/01.mpa.0000186249.89081.0d · Cited by 48 · cited 1×
“Of those with radiologic followup, 74% of patients were noted to have tumor load control at a median of 21 months after the procedure.”
MethodKim, S., Kim, J. W., Han, S., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Heo, D. S., & Bang, Y. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-448 · Cited by 48 · cited 1×
“worse response to chemotherapy as compared to NETs [58].”
BackgroundMolecular mechanisms of metastasis
Hoon, D. S. �., Ferris, R. L., Tanaka, R., Chong, K. K., Alix‐Panabières, C., & Pantel, K. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21690 · Cited by 42
Neuroendocrine Liver Metastases
Reddy, S. K., & Clary, B. M. (2010) · Surgical Clinics of North America · doi:10.1016/j.suc.2010.04.016 · Cited by 38
Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women
Das, B. C., Gopalkrishna, V., Das, D. K., Sharma, J. K., Singh, V., & Luthra, U. K. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1<42::aid-cncr2820720110>3.0.co;2-s · Cited by 35
Interferon-α-2a Is a Potent Inhibitor of Hormone Secretion by Cultured Human Pituitary Adenomas
Hofland, L. J., de Herder, W. W., Waaijers, M., Zuijderwijk, J. M., Uitterlinden, P., van Koetsveld, P. M., & Lamberts, S. W. J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.6005 · Cited by 31 · cited 1×
“Interferons have multiple antitumor effects [79], and they may upregulate somatostatin receptors in NETs [80], thereby providing a useful combination therapeutic option.”
BackgroundHoffmann, R., Paprottka, P. M., Jakobs, T., Trumm, C. G., & Reiser, M. (2011) · Abdominal Imaging · doi:10.1007/s00261-011-9753-6 · Cited by 29 · cited 1×
“Given these new options, the clinician can tailor therapy specific to the patient diagnosed with NLM, thereby giving the patient the best possible chance of prolonged survival.”
BackgroundManagement of Advanced Neuroendocrine Tumors With Hepatic Metastasis
Khasraw, M., Gill, A. J., Harrington, T., Pavlakis, N., & Modlin, I. M. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181b152a1 · Cited by 28 · cited 4×
“Similar to PRRT, the level of uptake on somatostatin scintigraphy may be an indicator of patient’s response to SSA therapy [44].”
BackgroundInfluentialDeng, G., Zhao, D.-L., Li, G., Yu, H., & Teng, G. (2011) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0179-x · Cited by 28 · cited 2×
“However, tumor size was not significantly different between these two groups [35].”
BackgroundMartin, M. E., Tarara, D., Wu, Y.-M., Ukah, F. O., Fabrega, A. J., Corwin, C., Lang, E., & Mitros, F. A. (1996) · PubMed · Cited by 28
Kang, J. Y., Choi, M. S., Kim, S. J., Kil, J. S., Lee, J. H., Koh, K. C., Paik, S. W., & Yoo, B. C. (2010) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2010.16.4.383 · Cited by 26 · cited 2×
“Although studies on patients with NLMs are limited, in one study of 32 patients with hepatocellular carcinoma, the authors found that there was no survival advantage in patients with preoperative HACE prior to surgical resection [32].”
BackgroundAc, G., Kotylak, G., & BITTER-SUERMANN, H. (1991) · PubMed · Cited by 23
Sunitinib paves the way for targeted therapies in neuroendocrine tumors
Raymond, É., Faivre, S. J., Hammel, P. R., & Ruszniewski, P. B. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0130-0 · Cited by 22 · cited 1×
“The more the tumor expresses somatostatin receptors as compared to the surrounding tissue, the more effective the PRRT will be.”
BackgroundCarboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study
Jodrell, D. I., & Smith, I. E. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf02940296 · Cited by 16 · cited 1×
“Cholelithiasis may arise in up to 50% of patients due to inhibition of gallbladder contractility [41], but only a handful will develop symptoms requiring cholecystectomy [78].”
BackgroundFaiss, S., Scherübl, H., Riecken, E. O., & Wiedenmann, B. J. (2009) · Digestion · doi:10.1159/000201404 · Cited by 16 · cited 1×
“Two demonstrated increased 5-year survival rate [70] and median survival time [83] in the combination group versus the octreotide-only group, 57% versus 37% and 51 months versus 35 months, respectively; but another trial showed minimal response rates [84].”
ResultHao, M., Lin, H., Chen, Q., Wu, H., Yu, W., & Chen, T.-G. (2007) · PubMed · Cited by 11
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Research works printed but not linked: 21
- 2009, 96, 175
- 1990, 108, 1091
- 1998, 66, 1307
- 2002, 73, 386
- 1996, 62, 724
- 2007, 26, 861
- 2011, 18, 127
- 1999, 81, 1351
- 1985, 253, 2741
- 1986, 315, 663
- 1998, 77, 632
- 1991, 30, 503
- 1993, 72, 244
- 1993, 32, 225
- 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 · doi:10.1002/(sici)1097-0142(20000215)88:4<770::aid-cncr6>3.0.co;2-0
- 1991, 23, 2197
- 2009, 31, 169
- 1990, 26, 62
- 2000, 118, 735
- 1999, 84, 3336
- 1996, 57, 84
Cited by
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
“Another option with neuroendocrine liver lesions, given that the majority of them are hypervascular, is hepatic directed procedures, which include ablative therapy, transarterial embolization, transarterial chemoembolization, and selective internal radiation therapy with yttrium-90 microspheres.(117) Systemic, i.”
BackgroundIto, T., Igarashi, H., Uehara, H., Berna, M. J., & Jensen, R. T. (2013) · Medicine · doi:10.1097/md.0b013e3182954af1 · Cited by 217
Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management
Sahani, D. V., Bonaffini, P. A., Fernández–Del Castillo, C., & Blake, M. A. (2013) · Radiology · doi:10.1148/radiol.12112512 · Cited by 191
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“These cases highlight instances where PRRT achieved remarkable therapeutic responses, demonstrating its efficacy by delivering targeted radiation to NET cells while sparing healthy tissues [102].”
BackgroundTherapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances
Ito, T., Igarashi, H., & Jensen, R. T. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0642-8 · Cited by 124
“debulking surgery is not recommended where resection cannot be complete or cannot result in the removal of [90 % of the metastatic tumor, because studies show this does not result in improved survival compared with that in patients who do not undergo debulking surgery [21, 25, 26, 98, 101, 102].”
Influential
Metadata
- Authors
- Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- O'Mahony, Christine A.
- Venue
- International Journal of Hepatology
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-11
- ISSN
- 2090-3448 (ISSN-L)
- 2090-3456
- PMC
- PMC3195553
- OpenAlex
- W2108019032
- Cited by
- 69
- References
- 103
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2021: 6 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 7 · 2013: 8 · 2012: 8
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Hepatology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- neuroendocrine liver metastases, neuroendocrine tumors, hepatectomy, orthotopic liver transplantation, radiofrequency ablation, hepatic artery embolization, hepatic artery chemoembolization, radioembolization, peptide receptor radionuclide therapy, somatostatin analogues, interferon-alpha, mTOR inhibitors, vascular endothelial growth factor, microRNA, systemic chemotherapy, biologic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
